IGC
IGC Pharma, Inc.
stockNYSEAMERICAN
igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.27 | 2026-09-28 | +0.36% | 2.897 |
| 1M | 0.30 | 2026-09-04 | -7.72% | -0.425 |
| 3M | 0.28 | 2026-07-06 | -2.13% | 1.357 |
| 6M | 0.27 | 2026-04-06 | +2.57% | 1.307 |
| 1Y | 0.41 | 2025-10-03 | -32.22% | 1.186 |
| 2Y | 0.37 | 2024-10-04 | -25.78% | — |
| 5Y | 1.46 | 2021-10-04 | -81.16% | 0.778 |
IGC Pharma, Inc. (NYSEAMERICAN:IGC) stock price today is $0.28, and today's volume is 633,241. IGC is up 1.852% today. The 30 day average volume is 741,206. IGC market cap is $28.43M with 103.38M shares outstanding.